Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association  by Bitan, Menachem et al.
Biol Blood Marrow Transplant 22 (2016) 96e103Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgClinical Research: PediatricDetermination of Eligibility in Related Pediatric Hematopoietic
Cell Donors: Ethical and Clinical Considerations.
Recommendations from a Working Group of the Worldwide
Network for Blood and Marrow Transplantation AssociationMenachem Bitan 1,*, Suzanna M. van Walraven 2, Nina Worel 3, Lynne M. Ball 2, Jan Styczynski 4,
Marta Torrabadella 5, Volker Witt 6, Bronwen E. Shaw7, Adriana Seber 8, Hiromasa Yabe 9,
Hildegard T. Greinix 10, Christina Peters 6, Eliane Gluckman 11, Vanderson Rocha 12, Joerg Halter 13,
Michael A. Pulsipher 14
1 Pediatric Blood and Marrow Transplantation & Immunotherapy Program, Department of Pediatric Hematology/Oncology, “Dana-Dwek” Children’s Hospital, Tel-Aviv
Sourasky Medical Center, Tel-Aviv, Israel
2Department of Pediatrics, Stem Cell Transplantation Unit, Willem Alexander Children’s Hospital, Leiden University Medical Centre, Leiden, the Netherlands
3Department of Transfusion Medicine, Medical University of Vienna, Vienna, Austria
4Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
5Blood and Tissue Bank, Barcelona, Spain
6Department of Pediatrics, St. Anna Kinderspital, Medical University of Vienna, Vienna, Austria
7Center for International Blood and Marrow Transplant Research, Froedtert and the Medical College of Wisconsin, Clinical Cancer Center, Milwaukee, Wisconsin
8 Pediatric Oncology Institute, Sao Paulo, Brazil
9Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Kanagawa, Japan
10Medical University of Graz, LKH-University Klinikum Graz, Division of Haematology, Graz, Austria
11Department of Hematology, Eurocord Ofﬁce, Hôpital Saint-Louis, Paris, France
12Oxford University Hospitals NHS Trust, Department of Clinical Haematology, Bone Marrow Transplant Unit, Cancer and Haematology Centre, Churchill Hospital,
Oxford, UK
13Department of Hematology, University Hospital Basel, Basel, Switzerland
14Division of Hematology/Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children’s Hospital, Salt Lake City,
UtahArticle history:
Received 24 May 2015
Accepted 12 August 2015
Key Words:
Allogeneic hematopoietic cell
transplantation
Bone marrow and peripheral
blood stem cell donor
Pediatric organ donationFinancial disclosure: See Acknowl
* Correspondence and reprint re
diatric Blood and Marrow Transp
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2016 American Sociea b s t r a c t
Related donors for hematopoietic cell (HC) transplantation are a growing population in recent years because of
expanding indications for allogeneic transplantation. The safety andwelfare of the donor aremajor concerns for
the transplantation community, especially for related sibling donors of young recipients who are children and,
thus, not able to fully consent. Because donation of HC does not improve the donor’s own physical health and
carries a risk of side effects, careful assessment of medical risks speciﬁc to the individual donor, as well as
consideration of ethical and legal aspects associatedwith donation froma child,must be considered. In addition,
donor centers must balance the needs of both the donor and the recipient, understanding the inherent conﬂict
parents may have as they can be overly focused on the very sick child receiving a transplant, rather than on the
relatively less signiﬁcant health or emotional problems that a sibling donor may have, which could impact risk
with donation. Likewise, consideration must be made regarding the nature of the relationship of the sibling
donor to the recipient and also aspects of performing researchonpediatricHCdonors. In this article, asmembers
of theDonor Issues Committeeof theWorldwideNetwork for BloodandMarrowTransplantation,we reviewkey
ethical concerns associated with pediatric donation and then give recommendations for screening potential
child donors with underlying health conditions. These recommendations are aimed at protecting the physicaledgments on page 102.
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ty for Blood and Marrow Transplantation.
M. Bitan et al. / Biol Blood Marrow Transplant 22 (2016) 96e103 97and emotionalwell-being of childhooddonors and arise out of the Third International Conference onHealth and
Safety of Donors sponsored by the Worldwide Network for Blood and Marrow Transplantation.
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Allogeneic hematopoietic cell (HC) transplantation is an
acceptable therapeutic tool for a growing number of pedi-
atric medical indications. HLA-matched siblings are consid-
ered to be the best donors for both practical and biological
reasons, including superior availability before and after
transplantation [1-6]. Thus, when the recipient is a child,
potential sibling donors may be children themselves.
Moreover, in rare cases, children may also be considered as
potential donors for an adult sibling, parent, or other family
member. Worldwide data demonstrate that more than one
third of children undergoing allogeneic transplantations
receive grafts from siblings under the age of 18 [7,8]. All 3
major sources of stem cells, bone marrow (BM), peripheral
blood stem cells (PBSC), and cord blood (CB), are routinely
obtained from pediatric donors, but BM-derived cells are the
preferred source for many indications [7,8]. According to
an European Group for Blood and Marrow Transplantation
(EBMT) estimate, approximately 600 to 700 children in
Europe become hematopoietic stem cell donors for their
siblings every year [9].
The key issue that must be addressed with childhood HC
donors is their initial inability to understand and voluntarily
consent. Understanding increases as they age into an ability
to assent, then ﬁnally to legally consent. Because HC dona-
tion can beneﬁt their sibling more than any other tissue
source, and because the procedure can be performed with
limited risk, sibling donation under parental consent has
been considered appropriate by many, and an extensive
literature has developed that addresses the ethical un-
derpinnings of this practice [10]. Authors have suggested
that this act is necessary “involuntary altruism” in one not
capable of recognizing the need [11]; others have suggested
the parents are providing “substituted judgment” of what an
adult would do under similar circumstances [12], and yet
others have preferred framing the donation as something
done in the “best interest” of the child, given the impact on
the family framework of nondonation [11,13,14]. Another
proposed framework uses the “intrafamilial principle,”
where members of a family have an obligation to other
family members, making trade-offs for the good of the family
as a whole; a variation to this is the “intimate attachment”
principle, where because of a close attachment, the good of
the donor is bound up in the good of the recipient. Though
ethical frameworks may vary, all agree that such donation is
reasonable but safeguards are necessary to protect the psy-
chological and medical health of the child, to consider the
health and the implications of the donation distinctly from
the ill sibling, and to respect the child donor’s developing
sense of autonomy and ability to assent.
The Worldwide Network for Blood and Marrow Trans-
plantation believes that minors can physically and ethically
participate as hematopoietic stem cell donors. This state-
ment reviews consensus recommendations of an interna-
tional working group regarding 3 important areas of medical
ethics associated with pediatric HC donation and then ad-
dresses concerns regarding pre-existing medical issues that
some potential pediatric donors may have, which couldaffect their safety during stem cell donation. With a global
perspective, we provide recommendations for how donors
should be approached regarding advocacy and parental
rights, and then we outline conditions when it may not be in
the best interest of a child to be a donor for HC therapy. This
article is not an exhaustive review; instead, we have chosen
to focus on limited areas we think are of importance. Our
intent is to begin an active process of recommendations
regarding pediatric donor guidelines that will be updated
regularly.
ADVOCACY VERSUS PARENTAL RIGHTS
Donation of BM from a sibling or close family member
who has not reached legal status for offering independent
informed consent has been practiced for nearly 4 decades
and is considered by most experts and ethicists to be an
appropriate procedure as long as care is taken to ensure the
health and safety of the donor [14,15]. Donation of PBSC by
sibling minors using granulocyte colonyestimulating factor
(G-CSF) has also been widely practiced for more than 15
years, has extensive safety data, and is considered standard
by many centers and countries, although there are variations
in the acceptability of the approach dependent on the age of
the donor [9,10,16]. Themain safeguards of the interest of the
healthy sibling donor since the inception of the practice have
been the parents and the physicians involved in the proce-
dure, generally part of the transplantation team caring for
the affected child. (Although some countries and states have
used court-appointed advocacy systems, these have been the
exception, rather than the rule). However, concern has arisen
that conﬂicts of interest could possibly lead to the perfor-
mance of HC collection in situations that would favor the
health of the sicker recipient sibling over that of the donor.
This has led to statements both from the American Academy
of Pediatrics (AAP) [15] and the World Marrow Donor As-
sociation (WMDA) [17] calling for (1) an unbiased health
screening and consent process performed by physicians or
equivalent health care providers who are not involved in the
care of the sibling, and (2) assessment of the relative risks
and beneﬁts of collection of a given donor by an independent
advocate, who may or may not be the health professional
screening the patient.
Although smaller transplantation programs may ﬁnd it
difﬁcult to identify and schedule individuals qualiﬁed in
donor screening who are not involved in the recipient’s
evaluation and care, this approachmakes sense andwill soon
become standard practice. A survey performed by the Center
for International Blood and Marrow Transplant Research
Donor Health and Safety Committee published in 2010
showed that physicians at 70% of centers were involved in
overlapping care of the donor and the recipient during the
donor evaluation, clearance, and collection phases. Their
publication included an admonition that “the transplant
community . eliminate [this] potential for conﬂict-of-
interest. [Donor clearance should be performed by] physi-
cians whose ﬁduciary responsibility is to only one individual
as is required by the NMDP for unrelated donors and by the
[solid] organ transplantation ﬁeld” [18]. An observation by
M. Bitan et al. / Biol Blood Marrow Transplant 22 (2016) 96e10398the EBMT Nurses Group conﬁrmed similar situations in
Europe [19]. These publications and statements, along with
the AAP and WMDA pronouncements, have led to incorpo-
ration of this principle into the next (6th) edition of the
Foundation for the Accreditation of Cellular Therapy and
Joint Accreditation Committeeethe International Society for
Cellular Therapy (Europe) and EBMT standards, requiring all
certiﬁed centers to adopt this approach.
Although medical screening by an independent practi-
tioner can protect donors from harm if they have signiﬁcant
medical issues, there is a lingering question about whether
medical screening alone is adequate and about whether true
advocacy for the donors is being performed. The WMDA
statement calls for the donor to be screened by someonewith
a “documented advocacy role.” The AAP statement states that
“the donor advocate should help the parents weigh the risks
and beneﬁts for the healthy child to serve as a hematopoietic
donor for an ill familymember and not just weigh the risks and
beneﬁts from the perspective of the potential recipient or from
that of the family as a unit.”What this implies is that the donor
advocate should have the ability to look at the potential harm,
even if relatively minor compared with that for the sick sib-
ling, and potentially advise against donation if there is a
reasonable risk of either physical or psychological harm to the
donor. Furthermore, if there is either medical history or clin-
ical ﬁndings that raise concern, the advocate could suggest
that a second opinion be obtained.
This shift in focus away from medical screening alone to
independent advocacy by either the screening physician or
another designated advocate means that there is the po-
tential for conﬂict between the donor advocate and the
parent or between the donor advocate and the screening
physician regarding whether a sibling should be able to
donate. This conﬂict could even occur between the sibling
and the advocate if the sibling is old enough to offer assent.
How can such conﬂicts be resolved? In states or countries
where a court has already assumed a protective role for a
donor, an advocate could easily appeal to a judge as part of
the standard approval process. When the court is not a
standard part of such proceedings, we recommend appeal to
the independent ethics board, associated withmost pediatric
hospitals that are transplantation centers. If deliberations of
such a board are felt to be inadequate by either contesting
party, however, such a board will not have legal authority,
and a court would be necessary for a legally binding decision.
If an advocate is given power to perform the roles out-
lined in the AAP and WMDA statements, who should ﬁll this
role? The most important qualiﬁcations are (1) training
regarding potential psychological and physical consequences
of donation, (2) understanding the ethical and legal basis
(according to country/state of origin) of voluntary HC
donation, and (3) independence from conﬂicts of interest
that would allow unbiased assessment of the welfare of the
child donor. We believe that not only medical personnel
trained in advocacy could perform this function, but also
social workers or mental health professionals trained to
understand medical issues (or in consultation with inde-
pendent medical health professionals) could ﬁll this role.
Health professionals associated with a transplantation team
are well equipped to accept the role as donor advocate as
long as they are not simultaneously involved in direct care
for the affected sibling. Individuals independent from the
transplantation team could also perform this role, but they
must be trained sufﬁciently and perform the duty often
enough to be competent in the role.NATURE OF THE RELATIONSHIP OF THE SIBLING DONOR
TO THE RECIPIENT
The AAP statement regarding HC donation advises that
speciﬁc conditions be met for collection from a minor sibling
donor to be permissible. Condition 2 requires that there has
to be a “strong personal and positive relationship, or in the
case of directed cord blood transplant, that a strong personal
and positive relationship has to be anticipated.” According to
the statement, this will “increase the likelihood that the
donor will experience some psychological beneﬁt.” Our
committee disagrees with the premise of this condition and
would like to propose a modiﬁcation.
The AAP statement argues that “it would be morally
problematic to ask a minor to serve as a donor to an un-
known, emotionally distant, or emotionally abusive relative.”
Examples are given of (1) a case of a child asked to donate to
a sibling theywere unaware of and (2) a case of a sibling who
was required to donate to an older sibling who had sexually
assaulted her. In the ﬁrst case, it is possible that a donor could
experience a signiﬁcant beneﬁt from learning of and estab-
lishing a relationship with an unknown sibling. In the second
case, however, the likelihood of psychological harm is so high
that most experts would agree that the child should never
have been HLA typed. The major challenge with the AAP
statement is that it is very difﬁcult to assess whether given
sibling’s relationships are positivedsuch relationships vary
tremendously through the years and have the possibility of
being strengthened by a donation procedure. Rather than
assuming that a personal and positive relationship will more
likely result in a psychological beneﬁt to the donor, we think
it makes more ethical sense to focus on avoiding psycho-
logical harm.
Practically, how can this is approached? First, if siblings
have no personal relationship with each other (parents live
separately and do not desire any interaction of the children
now and in the future), it is best to avoid the conﬂict by not
performing HLA typing. On the other hand, if separated
parents want to use this as an opportunity for siblings to get
to know each other, and a future relationship potentially
desirable to both individuals could occur, then as long as the
child assents, HLA typing and donation are reasonable. In
such a circumstance, the likelihood of psychological harm is
low.
What about siblings with negative relationships? If the
relationship is extremely negative, such as in the case of
sexual or repeated physical or emotional abuse, HLA typing
should not be performed. Although parents may not be
aware of such abuse, a donor advocate should screen for
these rare issues. How about the more frequently encoun-
tered situation, where siblings ﬁght regularly and currently
don’t like each other? If such siblings have the possibility of a
positive or nonsigniﬁcantly negative relationship, and if the
potential donor is at the age of assent and voluntarily assents,
donation seems reasonable. Obviously, situations where
siblings/relatives don’t know each other personally should
be carefully assessed by an advocate before HLA typing is
performed. All siblings should be screened for seriously
negative relationships as they go through the donation
screening process, preferably before HLA typing, as well.
PERFORMING RESEARCH ON PEDIATRIC HC DONORS
The Ethics and Clinical Working Groups of the WMDA
recently published guidelines outlining what they think
should and should not be classiﬁed as research related to
unrelated donors [20]. Because products obtained from the
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collection can be used in many ways, it is sometimes difﬁcult
to determine when a donor should be considered a research
subject and required to undergo research consent, according
to the principles of the Declaration of Helsinki. The WMDA
groups suggested 2 categories where donors are undergoing
research. The ﬁrst is themore obvious category, “where there
is an intervention or interaction with the donor for research
purposes.” Examples of interventions/interactions include
use of a new cytokine designed to mobilize PBSC, randomi-
zation between collection approaches, or participation in a
survey about donor attitudes. Because of the direct interac-
tion and collection of research data, research consent is
obviously necessary. The second category of research in-
cludes studies that gather individually identiﬁable research
material, even if coded, that are beyond the standard de-
mographic data on patients gathered by registries. The
WMDA position paper gives relevant examples that clarify
these statements [20]. Donors should not be considered
research subjects simply because the recipients are enrolled
on research protocols. Our committee agrees with these
recommendations and believes that applying them to the
related donor setting is appropriate.
Once a pediatric donor has been declared a research
subject, regulations regarding research in pediatric subjects
(subjects not fully able to undergo consent) apply. Such
regulations vary by country or state, but all regulatory
frameworks struggle to offer protection to the healthy donor
because of the following: (1) collection procedures involve a
small risk of serious complications and a moderate risk of
temporary discomfort, (2) these procedures are well estab-
lished and considered standard procedures potentially not
subject to research regulation, (3) there is controversy about
whether a donor has a “condition” because they are generally
healthy bystanders in the process of a disease their sibling is
ﬁghting, and (4) it is difﬁcult to assess whether the donor
will gain direct beneﬁt from a collection procedure, as many
ethicists are hesitant to consider possible indirect psycho-
logical beneﬁt gained from contributing to a family need as
something that would meet a standard of direct beneﬁt.
An example of the challenges faced in ﬁtting HC donor
research from healthy minors into regulatory rules designed
for children who have an illness or health condition is found
in United States regulations. For research to be performed on
children, (1) the donor must experience direct beneﬁt
(known as the 405 rule) (Figure 1), or (2) the research must
represent at most a minor increase over minimal risk andMinimal Risk
(MR)
Minor Increase 
over MR
More than 
Minor Increase 
over MR
Prospect 
‘Direct’ 
Benefit 46.404
Approvable by 
IRB for all 
children
46.405
Approvable by IRB if prospect of 
‘direct’ benefit justifies risks
NO
Prospect 
‘Direct’ 
Benefit
46.406
Approvable by 
IRB if research 
concerns 
subject’s 
condition
46.407
Approvable only 
by Government 
Panel*
*Special panel is being convened to decide whether the research is appropriate; if the panel 
agrees, the research will then be approved by top oﬃcials in the federal government.
Figure 1. United States Pediatric Risk-Beneﬁt Regulations (45CFR46,
Subpart D).address a “condition” the subject has (406 rule) (Figure 1), or
(3) if either of these conditions don’t apply, a special panel
must be convened to decide whether the research is appro-
priate; if the panel agrees, the researchwill then be approved
by top ofﬁcials in the federal government. Minimal risk is
deﬁned as risk not greater than the average risks children
face in life. Because a collection procedure is more than
minimal risk, a change in such a procedure for research can
often be construed as muchmore than minimal risk. Because
it is difﬁcult to deﬁne a beneﬁt to the donor from the pro-
cedure, some reviewers ﬁnd it difﬁcult to approve any
research on donors under rule 405. Other reviewers object to
calling the state of being an HLA-matched sibling of a person
with a disease a “condition” that research can address, thus
making approval under rule 406 problematic. The only other
avenue, if this line of interpretation of these regulations is
followed, is a rule 407 review (Figure 1). Obviously, research
regulations that require almost all new research to convene a
government panel to addressmerit and obtain approval from
highest levels is not practicable.
As a committee, we feel that research that will (1)
improve the collection process by making it safer or more
efﬁcient, (2) allow biological correlation of donor and/or
recipient characteristics that will better deﬁne outcomes of 1
or the other, or (3) improve survival of the recipient based
upon minor changes in collection or manipulation of the
product should be encouraged. We feel that because collec-
tion of BM and PBSC is a well established, safe procedure,
judgments made about the safety of a research procedure
should start with the inherent risk associated with the
accepted procedure as a baseline. In other words, because the
donor could be having a BM harvest as a standard procedure,
does a change in the procedure proposed as research result
in increased risk to the donor above the baseline risk, and if
so, is it a minimal increase in risk?
We also believe that some consideration should be made
to the reality that when a family donor is identiﬁed as being
an appropriate HLA match (or a haploidentical match in the
case of this form of transplantation), if they assent (if old
enough), and if they are otherwise healthy, that child will
likely participate in a collection procedure, whether or not
research is involved. Although being a donor is not a medical
condition, it is a situationwhere an individual both desires to
help and has a special ability to help “save” their family
member. A reasonable term to refer to this condition would
be “willing and eligible donor,” and because he or she is
going to donate in a standard of care fashion if research is not
involved, as long as the research is deemed minimal risk
above the procedure he or she would have otherwise, it
seems reasonable and appropriate to allow such research to
occur. Along a similar vein, if the direct purpose of the pro-
posed research is to improve the collection process by
making it safer or more efﬁcient (decreasing risk by having
fewer or shorter collection procedures), a study may provide
a potential beneﬁt for the “condition” of being a donor.
Therefore, in this circumstance, it may be reasonable to
consider risks that are more than minimal risk.
CLINICAL ISSUES WITH THE DONOR THAT COULD
INCREASE RISK
Over the last few decades, research has concentrated
more on psychosocial effects than on physical outcomes of
pediatric donors. We think that there are many clinical issues
often seen in normal pediatric HC donors that should be
addressed to avoid unnecessary risk. It is important to
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child to a potentially harmful medical procedure with no
direct clinical beneﬁt, and therefore, in spite of the good that
can be done for the donor’s ill sibling, because other donor
sources can be used, the donor’s safety must be top priority.
Clinical dilemmas may be subdivided according to the
timeframe of the donation: before, during, and after dona-
tion. In this section, we will deal mainly with the “before”
topics, including situations where the potential donor carries
a medical problem/disease but normal BM, as opposed to the
situation where a potential donor carries a problem in her/
his BM but has no physical limitation to donation. We will
also point out medical risks that one should pay attention to
while taking care of a pediatric donor.
Medical Risks and Beneﬁts
Currently, most medical ethicists agree that the act of
donation provides no direct medical beneﬁt to the donor.
However, risks for the healthy donor occur in every type of
donation. Approximately 1.1% of donation procedures will
have some type of signiﬁcant complication; the estimated
death incidence is 1 per 10,000 donations, although deaths
have not been reported in pediatric donors [21,22]. The
source of the stem cell donation has the greatest inﬂuence on
what type of adverse events will emerge. Side effects include
pain, either from G-CSF treatment, placement of central
venous catheter (CVC) or the direct punctures made when
harvesting bone marrow. Most young donors will require a
CVC, thus exposing them to potential risks such as bleeding,
pneumothorax, and complications of sedation or general
anesthesia [9,16]. Blood product transfusion is yet another
risk. Younger age and higher harvest volume put the donor
in higher risk for requiring allotransfusion, potentially
exposing donors to risk of transfusion transmitted infec-
tion including bacteria, viruses, parasites, and prions. Even
without receiving blood products, donors often need iron
supplementation after donation.
PBSC as a graft source from pediatric donors becamemore
popular in the last decade [23-25]. Though still not the major
source for stem cells, peripheral bloodederived stem cell
harvesting requires special attention in children, with the
use of growth factors being the main issue. Long-term
adverse effects from a brief treatment course with G-CSF
for the harvest of PBSCs is being studied in on-going in-
vestigations, but to date no convincing evidence has shown
signiﬁcant health risks [10,26]. That said, one has to keep in
mind the long life expectancy of children comparedwith that
of adult donors, and this issue should be followed closely.
Therefore, we recommend that G-CSF be used with caution
only when needed, and we emphasize the need for long-
term follow-up for these donors as published previously [27].
If a Donor has Signiﬁcant Issues, Avoid HLA Typing
A question has been made regarding the timeframe of
medical examination and HLA typing. Today, HLA typing
precedes physical examination of the potential donor. Cen-
ters ﬁrst screen for potential donors and physically examine
those found to be matched. We suggest that centers should
consider performing an independent medical screening that
would remove children with potentially serious medical
problems before HLA typing. If there is a medical contrain-
dication that does not allow a BM or PBSC collection, we
recommend that HLA typing should not be performed. Thiscan avoid guilt on the part of an individual who cannot safely
donate.Donors with Medical Problems
The AAP statement referenced previously recommended
that children may serve as stem cell donors only if they are
“medically appropriate.” No further details were provided.
We feel that this issue should be described withmore precise
criteria. Wewill discuss 2 broad areas that address this issue:
pediatric donors with medical problems, but with normal
BM, and pediatric donors with known or possible genetic
issues that may impact their recipient.
Donors with medical problems but normal BM
As a basic rule, it is preferable that a pediatric donor has
no major medical problems. The question of including po-
tential donors or deferring them starts when medical signs
and symptoms are discovered. In the Netherlands, for
example, many donors are accepted for PBSC donation
despite the presence of conditions for which they would be
deferred if they were unrelated donors [28]. Because siblings
with health problems and their parents and donor centers
are motivated to use them as donors in spite of these medical
conditions, it is important to establish inclusion and exclu-
sion criteria to clarify what is appropriate. These criteria
need to be backed up by medical literature. However, in the
absence of literature addressing rare conditions, consensus
recommendations can be given.
The decision of whether to collect stem cells from BM or
from peripheral blood is usually dictated by the clinical
indication and approach to transplantation of the patient.
But one should also consider the donor’s safety in this choice,
especially when outcomes of the recipient are very similar
between the 2 stem cell types. Donors are excluded from
donating BM if there is contraindication for general anes-
thesia. This may be a challenge for PBSC in pediatrics, as
some centers require general anesthesia for CVC placement.
How should one approach donors with cardiac, lung, or
gastrointestinal illnesses?What about childrenwith diabetes
[29]? We recommend that these individuals undergo a
thorough evaluation by specialists in these organ systems or
diseases and engage in a dialogue with the medical profes-
sional clearing the donor about potential harm to the donor if
a given harvest procedure is performed. If it is clear that
there is a moderate risk of signiﬁcant harm, the donor should
be deferred. We recommend that transplantation centers
designate specialists in each of the above-mentioned disci-
plines who can become familiar with the special needs of
stem cell donation, and, thus, may better decide how and
what to recommend in each case. There are a number of
scoring systems for anesthesia risk that can be employed
[30].
In addressing the issue of when to defer, there is a need
for clariﬁcation of how much risk is acceptable in a normal
donor. Clearly, the medical and legal communities have
judged that standard BM and, in most countries, PBSC
donation procedures provide an acceptable risk proﬁle for a
pediatric donor. The standard that we would then suggest is
that if any medical condition is present in a pediatric donor
that alters the safety proﬁle of the BM or PBSC collection
procedure in such a way that more than a minimal increase
of risk occurs, the donor should be deferred.
Table 1
Pediatric Donors with Known or Possible Genetic Issues that May Impact Recipient
Disease Reference Statement
Glucose-6-phosphate dehydrogenase
deﬁciency
Pilo F, et al. Bone Marrow Transplant 2013;48:36-39. A G6PD-deﬁcient but otherwise healthy volunteer can
be selected as an HSC donor.
Sickle cell disease [31,32]
Kang EM, et al. Blood 2002;99:850-855.
There were no G-CSFerelated unanticipated adverse
events, severe adverse events, or technical difﬁculties
with HSC products collected from donors with the sickle
trait
Thalassemia major Mathews V, et al. Hematol Oncol Clin North Am
2014;28:1187-1200.
Sibling donors are encouraged but carrier status is not
speciﬁcally mentioned
Primary immune deﬁciencies Filipovich AH. Bone Marrow Transplant 2008;42:S49-
S52.
Sibling donors are encouraged but carrier status is not
speciﬁcally mentioned
Hurler syndrome [33,34] Although information on the carrier status (1 mutated
gene) of the MSDs is lacking, it is expected that the
many of the published donors were carriers, which has
lead to the observed lower enzyme levels in engrafted
MSD patients.
Stem cell failure syndromes Tolar J, et al. Biol Blood Marrow Transplant 2012;
18:S166-S171.
Sensitive and speciﬁc diagnostic tests are now available
and it is essential to screen sibling donors, to ensure that
an affected sibling is not used as a stem cell donor.
Myelodysplastic syndrome/familial
acute myelogenous leukemia
[35,36] Outcomes using affected sibling donors are suboptimal,
with failure in PBSC mobilization, slow and incomplete
engraftment, graft failure, early relapses and
predisposition to donor-derived myeloid malignancies.
Wiskott-Aldrich syndrome Ozsahin H, et al. Blood 2008;111:439-445.
Okuya M, et al. Bone Marrow Transplant 2010;45:607-
609.
Successful transplant was performed for X-linked
thrombocytopenia from a mild symptomatic carrier.
Chronic granulomatous disease Soncini E, et al. BJH 2009;145:73-83. Sibling donors are encouraged but carrier status is not
speciﬁcally mentioned
HSC indicates hematopoietic stem cells; MSD, matched sibling donor.
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unrelated donors in most situations are approaching that of
related donors, and in spite of a higher risk of GVHD, if the
donor’s health is potentially in peril, use of an unrelated
donor (even if not fully matched) is a viable alternative that
could both offer curative therapy to an ill sibling and protect
a child donorwith an underling conditionwho is at increased
risk of harm.
Pediatric donors with known or possible genetic issues that
may impact their recipient
When children with known or suspected genetic disor-
ders undergo transplantation from siblings, great care needs
to be taken to ensure that sibling donors either do not have
the condition or, in some cases, are not carriers. Table 1
shows disorders where carrier siblings have been shown
either to be acceptable or not recommended for trans-
plantation. These recommendations may vary over time as
we learn more about speciﬁc diseases, especially disorders
where high-level expression of enzymes is important to
clinical outcome.
There are other disorders where children may be un-
dergoing transplantation and there is a suspicion that the
child’s condition may be congenital, such as a child pre-
senting with aplastic anemia and some somatic character-
istics that could suggest an undiagnosed congenital
marrow failure syndrome. This is also the case in many
pediatric myelodysplastic syndromes [35-37]. In such cases,
the sibling should be carefully assessed for BM function,
and in some cases BM testing may need to be performed to
ensure that the marrow is healthy. Such assessment may
include measurement of CD34 numbers or colony-forming
units and/or morphologic characteristics that would sug-
gest that the “normal” donor may carry the same disease in
an earlier stage.Some carrier states of diseases may present speciﬁc
health risks to the donor. A number of reports have suggested
that PBSC not be collected on carriers of sickle cell disease
[29,38,39]. On the other hand, more recent publications have
demonstrated no adverse events in sickle cell carrier donors
receiving G-CSF and donating from peripheral blood [31,32].
Likewise, potential donors who are not euthyroid at baseline
may be at risk for severe deterioration in their thyroid-
related hormonal state after injections of G-CSF [29,40-42],
albeit this was documented in adults and was not studied in
pediatric donors. For Hurler syndrome carriers, there is evi-
dence that normal expression levels of enzyme after trans-
plantation are important in improving outcomes of the
recipient, and that lower chimerism and lower levels have
been noted using siblings who are carriers. Thus, there is a
suggestion that siblings who are carriers may not be the best
donor for these patients [33,34].
There are many other major diseases, including primary
immunodeﬁciencies, chronic granulomatous disease, or
thalassemia, where there is strong support for matched
sibling donors, but carrier status is not speciﬁcally men-
tioned in reports. One should expect that for autosomal
recessive diseases or x-linked diseases (receiving female
sibling BM transplantation), one half of the transplantations
will have utilized carriers. In all these cases, we feel that in
the absence of data to suggest otherwise, use of a sibling in a
carrier state is appropriate.
Finally, there is debate concerning use of children with
Down syndrome or other congenital syndromes resulting in
severe developmental delay. There is evidence to show poor
outcomes from BM donated by Down syndrome children
[43,44]; therefore, this practice is not recommended. If the
disorder leading to developmental delay is not known to lead
to poor outcomes in the recipient, then donation can be
considered, but because many of these children have
M. Bitan et al. / Biol Blood Marrow Transplant 22 (2016) 96e103102pulmonary, cardiac, or other medical issues, a careful review
of the risks they may encounter should be performed by
trained individuals as outlined above, and if their risks are
increased, they should be deferred as donors.
“CREATING DONORS” AND FAMILY CB BANKING
Parents will sometimes consider the option of “creating”
donor siblings via embryo selection with preimplantation
genetic diagnosis for CB or BM donation. This complex
medical and ethical issue deserves further discussion but is
beyond the scope of this manuscript. A review of this issue,
along with considerations regarding direct and family CB
banking, has been published previously [45].
CONCLUSIONS
Pediatric donors of HC can almost always safely donate
with parental consent and greatly beneﬁt their recipients
and their families. To protect them from rare situations when
their psychological or medical health may be at risk, we
recommend advocacy and careful medical review. Potential
family sibling donors with medical or psychological reasons
not to donate should not be HLA typed. Those with medical
conditions should be carefully examined by skilled pro-
fessionals, and if their risks of complications with collection
are increased, they should be deferred. Following these
simple principles, transplantation professionals can fulﬁll
their obligation to the generous normal childhood donors
under their care to “Primum non nocere”dﬁrst, do no harm.
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